Company intelligence / Profile preview

Sisram Medical

Caesarea, Haifa District, Israel

Ownership: Private
Employees: ~564
Development stage: Other

Overview

Sisram Medical is commercially active globally in the medical aesthetics market, with products for skin rejuvenation, hair removal, injectables (including recently NMPA-accepted DAXXIFY botulinum toxin), and a growing presence in dental aesthetics and home-use beauty devices. Its pipeline includes new injectables and advanced medical devices moving toward registration and launch in China and elsewhere[3].

Therapeutic areas: OtherDermatology
Modalities: DeviceInjectableSmall molecule (for cosmetic fillers/lipolytics)Biologic (for botulinum toxin, e.g., DAXXIFY)Peptide (for peptide-powered products)
Industry: Biotech

Partnerships

IBSA (distribution of Profhilo)Feidun (exclusive distributor in China)

Beyond the preview

Go deeper on Sisram Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sisram Medical.

Explore the full profile